Gapping up
In reaction to strong earnings/guidance: INFY +5.6%, HELE +3%, PLUG +2.7%
Other news: EXAS +35.8% (positive CMS determination over Cologuard), APT +26% (following 27% move higher yesterday with ongoing Ebola fears), SCMP +19.2% (Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA), ALXA +16.8% (provided update on ADASUVE U.S. Commercial Progress; Alexza shipped 32,278 units in the third quarter, completing the ADASUVE initial product inventory stocking), CVEO +12.6% (Greenlight capital discloses 9.99% active stake in 13D filing), STV +6.9% (cont volatility pre-mkt), ISIS +5.3% (reports data from ISIS-SMN Rx Phase 2 studies in infants and children with spinal muscular atrophy), VNET +4.7% (establishes joint venture with Foxconn (FXCNY)), ARIA +3.7% (announced that Pharmacovigilance Risk Assessment Committee of EMA concluded review of Iclusig and has recommended that Iclusig continue to be used in Europe in accordance with its already approved indication), BX +2.7% (planning advisory spin-off, according to reports), ECOL +2.5% (to replace MEAS in the S&P SmallCap 600), OXLC +2.1% (adopted repurchase program of up to $35 mln worth of common stock), KGJI +1.6% (announces initial shipment of 24-karat gold jewelry product samples to Middle East)
Analyst comments: SCMP +19.2% (upgraded to Buy from Hold at Maxim Group), NDLS +0.9% (initiated with an Outperform at BMO Capital Mkts ), WDC +0.7% (initiated with a Buy at Jefferies), NRP +0.7% (upgraded to Outperform from Market Perform at Wells Fargo), BUD +0.5% (added to Conviction Buy List at Goldman)